Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7319980 | 0.88 | GRM2 (0.49) | LTA4HSLC7A5GRM2GRM3KIF11 | |
| SCHEMBL9544124 | 0.88 | GRM2 (0.49) | LTA4HSLC7A5GRM2GRM3KIF11 | |
| SCHEMBL27644530 | 0.87 | POLB (0.44) | LTA4HSLC7A5CYP2C19L3MBTL1MEN1 | |
| SCHEMBL27644605 | 0.82 | LTA4H (0.39) | LTA4HSLC7A5KIF11AAK1MEN1 | |
| SCHEMBL29182085 | 0.82 | MMP8 (0.48) | GRM2GRM3CYP2C19MEN1KMT2A | |
| SCHEMBL8893618 | 0.81 | KIF11 (0.44) | LTA4HSLC7A5GRM2GRM3KIF11 | |
| SCHEMBL6704315 | 0.81 | AAK1 (0.39) | LTA4HAAK1CTSSCTSKATM | |
| SCHEMBL28356651 | 0.81 | AAK1 (0.39) | LTA4HAAK1CTSSCTSKATM | |
| SCHEMBL28750863 | 0.79 | AAK1 (0.39) | LTA4HSLC7A5AAK1CTSSCTSK | |
| SCHEMBL5286288 | 0.79 | GRM2 (0.62) | SLC7A5GRM2GRM3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023226965-A1 | ROCK INHIBITORS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-106232617-B | Polymyxin derivatives and their use in combination therapy with different antibiotics | 云顶新耀医药科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3116897-B1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS INC (US) | 2022-03-02 | — | — | EP | disclosed |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | SPERO THERAPEUTICS, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-3116897-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | New Pharma Licence Holdings Limited (MT) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015135976-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | NEW PHARMA LICENCE HOLDINGS LIMITED (MT) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322858-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | LTA4H 3013/4885SLC7A5 581/4885GRM2 4423/4885 |
| US-20170073373-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, RRP15 | LTA4H 3013/4885SLC7A5 581/4885GRM2 4423/4885 |
| US-20210221848-A1 | POLYMYXIN DERIVATIVES AND THEIR USE IN COMBINATION THERAPY TOGETHER WITH DIFFERENT ANTIBIOTICS | PNISR, MRPS18A, MRPS35 | LTA4H 2985/4885SLC7A5 512/4885GRM2 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.